MX2022008065A - 25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino liquido y metodos para preparar los mismos. - Google Patents

25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino liquido y metodos para preparar los mismos.

Info

Publication number
MX2022008065A
MX2022008065A MX2022008065A MX2022008065A MX2022008065A MX 2022008065 A MX2022008065 A MX 2022008065A MX 2022008065 A MX2022008065 A MX 2022008065A MX 2022008065 A MX2022008065 A MX 2022008065A MX 2022008065 A MX2022008065 A MX 2022008065A
Authority
MX
Mexico
Prior art keywords
methods
crystalline
25hc3s
colest
hidroxy
Prior art date
Application number
MX2022008065A
Other languages
English (en)
Inventor
Shawn Johnstone
Stephan D Parent
Jie Li
Robert Wenslow
Travis Lee Houston
Andrew Miksztal
Michael Holtz-Mulholland
Flavio Lopez
Howard Sard
Mario Gonzalez
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Publication of MX2022008065A publication Critical patent/MX2022008065A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En el presente documento se describen formas cristalinas y líquidas cristalinas de 25HC3S de sodio. La descripción incluye las Formas I, II, III, V, IX, XI y XIII de 25HC3S de sodio y combinaciones de los mismas. Las formas farmacéuticas de las formas, o combinaciones de las mismas, y métodos para tratar o prevenir enfermedades tales como hipercolesterolemia, hipertrigliceridemia y afecciones relacionadas con la acumulación de grasa y la inflamación (por ejemplo, enfermedad del hígado graso no alcohólico (EHGNA), esteatohepatitis no alcohólica (EHNA), hepatitis alcohólica, lesión renal aguda (IRA), psoriasis y aterosclerosis) se describen adicionalmente en el presente documento. También se proporcionan métodos para preparar 25HC3S.
MX2022008065A 2019-12-27 2020-12-23 25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino liquido y metodos para preparar los mismos. MX2022008065A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962954279P 2019-12-27 2019-12-27
PCT/US2020/066947 WO2021133976A1 (en) 2019-12-27 2020-12-23 Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same

Publications (1)

Publication Number Publication Date
MX2022008065A true MX2022008065A (es) 2022-07-27

Family

ID=76575692

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008065A MX2022008065A (es) 2019-12-27 2020-12-23 25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino liquido y metodos para preparar los mismos.

Country Status (14)

Country Link
US (1) US20230056273A1 (es)
EP (1) EP4081028A4 (es)
JP (2) JP2023508985A (es)
KR (1) KR20220119459A (es)
CN (1) CN115103591A (es)
AU (1) AU2020415462A1 (es)
BR (1) BR112022011358A2 (es)
CA (1) CA3165765A1 (es)
CL (1) CL2022001742A1 (es)
IL (1) IL294286A (es)
MX (1) MX2022008065A (es)
PH (1) PH12022551596A1 (es)
TW (1) TWI904127B (es)
WO (1) WO2021133976A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102593667B1 (ko) 2016-08-02 2023-10-24 버지니아 커먼웰스 유니버시티 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
US20230056273A1 (en) * 2019-12-27 2023-02-23 Durect Corporation Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
KR102745654B1 (ko) 2022-09-21 2024-12-20 현대모비스 주식회사 에어백 장치 및 그 전개 제어방법
AU2023411014A1 (en) * 2022-12-23 2025-08-07 Durect Corporation 25-hydroxy-cholest-5-en-3-sulfate choline, formulations thereof and methods for preparing, and medical uses of same
AU2022491085A1 (en) * 2022-12-23 2025-08-07 Durect Corporation Salts including crystalline salts of 25-hydroxy-cholest-5-en-3-sulfate and methods for preparing same
EP4417616A1 (en) 2023-02-14 2024-08-21 Ospedale San Raffaele S.r.l. Lxr antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5218700B2 (es) * 1973-02-16 1977-05-24
US4046760A (en) * 1976-07-01 1977-09-06 Merck & Co., Inc. Process for preparing 1-α-hydroxy cholesterol derivatives
GB1592170A (en) * 1977-01-07 1981-07-01 Hoffmann La Roche 1a-hydroxycholecalciferol-25-hydroxy esters and their use in radioimmunoassay
OA06115A (fr) * 1978-03-11 1981-06-30 Etat Du Procédé de réparation du dihydroxy-24,25 cholestérol .
JPH07309891A (ja) * 1994-05-17 1995-11-28 Nisshin Flour Milling Co Ltd ステロイド誘導体の製造法
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US20090143279A1 (en) * 2007-06-15 2009-06-04 Vamsi Krishna Mootha Methods and compositions for treating metabolic disorders
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
EP3086793B1 (en) * 2013-12-24 2022-05-11 Virginia Commonwealth University Use of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction
WO2018026837A1 (en) * 2016-08-02 2018-02-08 Durect Corporation Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride
US20230056273A1 (en) * 2019-12-27 2023-02-23 Durect Corporation Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same

Also Published As

Publication number Publication date
PH12022551596A1 (en) 2023-11-20
EP4081028A1 (en) 2022-11-02
JP2025121967A (ja) 2025-08-20
US20230056273A1 (en) 2023-02-23
JP2023508985A (ja) 2023-03-06
KR20220119459A (ko) 2022-08-29
EP4081028A4 (en) 2024-03-06
TWI904127B (zh) 2025-11-11
BR112022011358A2 (pt) 2022-08-23
WO2021133976A1 (en) 2021-07-01
TW202135829A (zh) 2021-10-01
CN115103591A (zh) 2022-09-23
AU2020415462A1 (en) 2022-06-23
IL294286A (en) 2022-08-01
CA3165765A1 (en) 2021-07-01
CL2022001742A1 (es) 2023-03-24

Similar Documents

Publication Publication Date Title
MX2022008065A (es) 25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino liquido y metodos para preparar los mismos.
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
PE20180690A1 (es) Composiciones de acido obeticolico y metodos de uso
EA202092001A1 (ru) Соединения для лечения болезни гентингтона
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
MX2018007022A (es) Metodos para tratar la enfermedad de huntington.
MX2022015243A (es) Antagonistas del receptor de lpa y usos de estos.
BR112016023269A8 (pt) uso de ácido (r)-2-(4-((2-etóxi-3-(4-(trifluormetil)fenóxi)propil)-tio)-2-metilfenóxi)-acético ou sal do mesmo na fabricação de um medicamento para tratar doença hepática gordurosa não alcoólica ou esteato-hepatite não alcoólica
BR112021025964A2 (pt) Formas de sal de ácido bempedoico e métodos para uso das mesmas
MX2020013104A (es) Agentes activos y metodos de uso para el tratamiento de trastornos metabolicos y enfermedad hepatica no alcoholica.
MX373840B (es) Sales de berberina, sales ursodesoxicolicas y combinaciones, metodos de preparacion y aplicacion de las mismas.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX383856B (es) Compuestos y composiciones para inhibir la actividad de shp2.
BR112016026809A2 (pt) compostos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol substituído como agentes de alvejamento de asgpr
BR112015010360A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno do mesmo que pode se ligar especificamente ao sítio ii de uma il-6 humana, seus usos, ácido nucleico, composição, vetor, célula, e processo para produzir a mesma
CU20190080A7 (es) Derivados de isoindolina útiles para tratar la esteatohepatitis no alcohólica y otras enfermedades de curación disfuncional del tejido y fibrosis
MX391804B (es) Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
CL2017001545A1 (es) Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida
NZ709803A (en) Compositions comprising 15-ohepa and methods of using the same
EP4053092A4 (en) LIQUID HUMIC ACID EXTRACT
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
BR112016029067A2 (pt) ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios?
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
AR128613A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa